EVE Health Group Limited (ASX:EVE)

Market Cap	5.28M -28.4%
Revenue (ttm)	1.15M -33.5%
Net Income	-1.89M
EPS	-0.01
Shares Out	352.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,102,750
Open	0.0150
Previous Close	0.0140
Day's Range	0.0150 - 0.0150
52-Week Range	0.0140 - 0.0320
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About EVE Health Group

EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property). Its lead product is the Dyspro, a formulation developed to address dysmenorrhoea and Endometriosis Pain; and Libbo, an oral dissolving film for erectile dysfunction. The company also develops Apixaban to treat anticoagulation. The company was formerly kno...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2003
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EVE

Financial Performance

In fiscal year 2026, EVE Health Group's revenue was 1.15 million, a decrease of -33.53% compared to the previous year's 1.73 million. Losses were -1.89 million, 19.7% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 21, 2026

Data Sources Report a data error